Search Results 21-30 of 27946 for %EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BDop%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BDr%EF%BF%BD%EF%BF%BD%EF%BF%BD%3Aza33%EF%BF%BD%EF%BF%BD%EF%BF%BD
Luk JH, Chang BF, Albus ML, Morgan SA, Szymanski TJ, Hamid OS, Keller L, Daher AF, Sheele JM. Emergency Medical Services Provider Self-Reported Occupational ...
McDade EM, Boeve BF, Fields JA, Kumar N, Rademakers R, Baker MC, Knopman BD, Petersen RC, Jack CR Jr, Kantarci K. MRS in early and presymptomatic carriers ...
Title: EF-32 (TRIDENT): A Pivotal Randomized, Open-Label Study of OPTUNE® (TTFields, 200KHZ) Concomitant with Radiation Therapy and Temozolomide for the ...
Pagali SR, Kumar R, LeMahieu AM, Basso MR, Boeve BF ... BD, Emslie GJ, Mayes T, Trivedi M, Wang L ... 03/08/2022; 2(2). Grant CW, Barreto EF, Kumar R ...
... BD, Pagnano MW, Berry DJ. The Chitranjan S ... EF, Perry KI, Abdel MP, Tande AJ. Sex-specific ... EF, Tande AJ. Microbiology of hip and knee periprosthetic ...
... EF. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns ...
... BD, Gossard AA, LaRusso NF, Gores GJ, Karlsen TH, Lazaridis KN. Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease ...
Izzy M, Addissie BD ... EF, Hassany SM, Moussa AM, Ugiagbe RA, Omuemu CE ... Yang JD, Ahmed F, Mara KC, Addissie BD, Allen AM, Gores GJ, Roberts LR.Hepatology.
McGuire SS, Finley JL, Gazley BF, Mullan AF, Clements CM. ... BD, Driscoll CL, Elder BD. Toothbrush ... EF, Bierle DM, Bosch W, Burger CD, Cano Cevallos ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift can go twice as far to advance cancer research and care!